ABSTRACT: Technetium-99m, the most commonly used radionuclide in nuclear medicine, can be attached to biologically important molecules through a variety of chelating agents, the choice of which depends upon the imaging application. The prostate-specific membrane antigen (PSMA) is increasingly recognized as an important target for imaging and therapy of prostate cancer (PCa). Three different 99m Tc-labeling methods were employed to investigate the effect of the chelator on the biodistribution and PCa tumor uptake profiles of 12 new urea-based PSMA-targeted radiotracers. This series includes hydrophilic ligands for radiolabeling with the [ 99m Tc(CO) 3 ] + core (L8−L10), traditional N x S y -based chelating agents with varying charge and polarity for the Tc]L8 produced the highest PSMA+ PC3 PIP to PSMA− PC3 flu tumor ratios and demonstrated the lowest retention in normal tissues including kidney after 2 h. These results suggest that choice of chelator is an important pharmacokinetic consideration in the development of 99m Tclabeled radiopharmaceuticals targeting PSMA.
■ INTRODUCTION
Technetium-99m (half-life, 6 h; γ-energy, 140.5 keV) is widely used in nuclear medicine because of its nearly ideal photon energy for single photon emission computed tomography (SPECT), low dose burden to the patient, low cost, ready availability, and synthetic tractability for incorporating into biological targeting agents. Despite the wide availability of PET isotopes (such as 18 Tc remains the radionuclide of choice for development of diagnostic radiotracers in most developing countries and is the most heavily utilized diagnostic medical isotope. 1 Adding further to its convenience, 99m Tc-labeled biotargeting agents can be prepared via a commercially available kit. A variety of well-established chelating agents is available for incorporating 99m Tc into biotargeting agents, however, the effects of various chelators and the composition of the 99m Tc core (inherent functionalities attached to 99m Tc) on the pharmacokinetics of the parent compounds have not been well characterized for specific indications. 2 Prostate cancer (PCa) is the most commonly diagnosed malignancy with few options for molecular imaging due to its relatively low metabolism. Prostate-specific membrane antigen (PSMA), an integral membrane protein, is increasingly recognized as a viable target for imaging and therapy of PCa.
3, 4 Elevated expression of PSMA is associated with metastasis, 5 androgen independence, 6 and progression 7 of PCa. We and others have previously demonstrated the ability of radiohalogenated, urea-based, low-molecular-weight inhibitors of PSMA to image PSMA expression in prostate tumor xenografts. 8 Tc(V)-oxo 17, 18 moieties. Generally, to retain binding affinity to PSMA, a linker was required between the PSMA-targeting moiety and the metal chelator. 16 While changes in the linker are known to affect the biodistribution of these agents, 16 ,17 the effect of various chelators and related 99m Tc-labeled cores on the pharmacokinetics of compounds of this class have not been well characterized.
Here we expand upon our earlier work with urea-based, PSMA-targeted imaging agents to address the effect of various common chelators of 99m Tc on the pharmacokinetics and tumor uptake in a small series of new imaging agents. Here we used three different 99m Tc core complexes and related chelating agents for comparison: (1) Tc labeling efficiency ( Figure 1 ). By altering the chelators for 99m Tc, the compounds produced consequently demonstrated differences in overall charge, lipophilicity, stability, and affinity, which we reasoned would alter their pharmacokinetics. Additionally, we briefly investigated the effect of aromatic substituents in the linker moiety on pharmacokinetics.
Imaging and biodistribution studies in NOD/SCID mice harboring PCa xenografts demonstrate that both tricarbonyl and 99m Tc-oxo complexes have favorable pharmacokinetics over the HYNIC-conjugated compound. Between the tricarbonyl and 99m Tc-oxo complexes, tricarbonyl complex [ 99m Tc]L8 exhibited superior tumor uptake and tumor-to-muscle and tumor-to-blood ratios that are suitable for clinical translation. Our studies also show that choice of chelating agent significantly affects the stability, affinity, lipophilicity, and ultimately pharmacokinetics of the final 99m Tc-labeled radioligands, suggesting that these results may have implications in the synthesis of 99m Tc-labeled imaging agents in general.
■ RESULTS
Chemical and Radiochemical Synthesis. Chemical and radiochemical syntheses are shown in Schemes 1−5. Compound L8 contains 1,4-disubstituted 1,2,3-triazole functionalized lysine as a chelating agent. 99m Tc labeling of this class of triazole containing chelators has recently been developed by Schibli's group 19 and was prepared through click chemistry 20, 21 as shown in Scheme 1. In particular, a click reaction was performed between commercially available fluorenylmethox- Tc-Labeled inhibitors of PSMA.
Scheme 1. Synthesis of L8 and ReL8
a ycarbonyl (Fmoc)-Lys(azide)-OH and Boc-Gly-propargyl-OH in the presence of a catalytic amount of Cu(OAc) 2 and sodium ascorbate and Tris-[(1-benzyl-1H-1,2,3-triazol-4-yl) methyl]-amine (TBTA) at ambient temperature followed by Fmoc removal to provide 1 in 45% yield. L8 was obtained upon coupling of 1 with the NHS ester of urea-suberate 2, 22 followed by removal of the Boc group using TFA/CH 2 Cl 2 /triethylsilane (TES) (1/1/0.05) in ∼60% yield. The rhenium tricarbonyl complex (ReL8) was synthesized by using [Re(CO) 3 (H 2 O) 3 ]-Br 23 as shown in Scheme 1. The monopyridyl monoacid lysine chelating agent was prepared in a multistep synthesis as outlined in Scheme 2. The acid group of Fmoc-Lys(Boc)-CO 2 H was protected using p-methoxy-benzyl chloride and Cs 2 CO 3 to obtain 3 in 70% yield. 16 Selective removal of the Boc group using p-toluenesulfonic acid in the presence of ethanol at ambient temperature provided 4 in 60% yield. Reductive amination of 4 with pyridine-2-aldehyde provided 5 in 40% yield. Alkylation of 5 by bromo-t-butyl-acetate at 25°C produced 6 in moderate yield (33%). Removal of the Fmoc group by 20% piperidine/DMF followed by removal of the PMB groups and the tert-butyl group by TFA/CH 2 Cl 2 at 25°C afforded the desired chelating agent 7, which was reacted with 2 to produce L9 in a yield of 60%. Compound L10 was prepared in two steps as described in Scheme 3. Reductive amination of imidozole-2-aldehyde with Fmoc-Lys-OH in the presence of NaBH(OAc) 3 and acetic acid followed by Fmoc removal provided chelating agent 8 in ∼30% yield. Chelating agent 8 was reacted with 2 to provide the PSMA-targeting ligand L10 in ∼50% yield.
A generalized Fmoc-based solid phase peptide synthesis strategy was developed with a combination of solution phase chemistry as required to prepare ligands L11−L18. Commercially available Fmoc-Lys(Boc)-Wang resin was conjugated with required amino acid residues, after which the compound was cleaved from the resin by an ice-cold mixture of TFA/CH 2 Cl 2 / triethyl silane (TES) (1/1/0.01) for 1 h at ambient temperature. After isolating the resin cleaved product 9, the free ε-amine of lysine was then conjugated with 2, followed by Fmoc removal and conjugation of the α-amine with the NHS ester of mercaptoacetic acid 24 to produce L11 as shown in Scheme 4.
Compound L19 was generated through a well-established labeling approach using the HYNIC chelating agent (Scheme 5 Tc] L13, whereas for all MAG-3 and MAS-3 conjugated radiotracers, only a single peak was isolated during radiolabeling. Interestingly, for all ligands except for L16, radiolabeling went smoothly using the S-trityl protected version of the ligand. Although both the protected and deprotected versions ultimately provide the same radiolabeled product, we used the protected starting materials to enable easier UV detection and separation by HPLC. A single set of HPLC conditions could be used to isolate radioligands [
99m Tc]L11−L18. Moreover, the S-trityl protected ligands proved stable in solution until subjected to radiolabeling conditions. Radiolabeling of the HYNIC adduct was performed according to a literature procedure by treating with tricine and SnCl 2 at ambient temperature for 30 min. 27 In Vitro Binding and Cell Uptake. All compounds demonstrated high binding affinity to PSMA with K i values ranging from 0.03 to 16.30 nM (Table 1) . We also synthesized an analogue of L8 that incorporates Re and observed a 3-fold improvement in binding affinity for ReL8 over L8 (Table 1) . Comparative cell uptake involving [ 99m Tc]L8 revealed ∼100 fold higher uptake in PSMA+ PC3 PIP cells relative to PSMA− PC3 flu cells. This uptake in PIP cells could be blocked by treatment with 10 μmol of the known, high-affinity PSMA inhibitor, ZJ43 (Supporting Information Figure S1 ). was observed even at 18 h, suggesting the opportunity for protracted imaging using these agents.
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As Figure S5 ), not only within the tumor but also within the renal cortex and salivary glands, confirming that uptake observed in these tissues is PSMA-mediated.
Among the MAG-2-chelated ligands, L11−L13, which possess different lipophilicities due to the presence of zero, one, and two Phe residues on the linker, respectively, considerable differences in nontarget tissue uptake was observed for their radiolabeled counterparts (Figure 3 Figure 3 and Supporting Information Figure S3 ). No significant difference was observed with respect to the tumor uptake, nontarget tissue uptake, or clearance between the isomeric compounds. Figure S6 ). SPECT-CT images of [
99m Tc]L19 demonstrated no specific uptake in PSMA+ tumor or kidneys (Supporting Information Figure S7 ) and provided diffuse and indiscriminant uptake throughout the tissues.
Biodistribution. On the basis of the SPECT-CT imaging results, [ Tc]L8, highest tumor uptake was observed at 30 min (28.3 ± 4.4% ID/g). PSMA+ PC3 PIP to PSMA− PC3 flu tumor uptake ratios were 53.9 ± 1.6 and 307.2 ± 24.2 at 30 min and 5 h, respectively. The distribution within normal organs and tissues was also favorable, with low blood and nonspecific tissue uptake and rapid clearance. The highest nonspecific uptake observed was in the liver, 28.9 ± 17.9% ID/ g, and spleen, 21.1 ± 8.5% ID/g at 30 min postinjection. However, those values decreased to 3.2 ± 0.4% and 1.8 ± 1.5%, respectively, by 5 h. Kidney uptake was expectedly high and Tc]L18, the latter, with two carboxylic acid groups from Asp residues on the chelator side chain, showed higher tumor uptake and lower accumulation of radioactivity in most normal tissues, including spleen, resulting in higher tumor-to-organ ratios than for [ 99m Tc]L15. To investigate the cause of the high spleen uptake for the 99m Tc-oxo compounds, two blocking studies were performed on selected organs using normal (nontumor) male CD-1 mice as shown in Table 6 , employing both 2-(phosphonomethyl)-pentanedioic acid (2-PMPA) 30 and ZJ43 for [ 99m Tc]L15. Greater than 90% of uptake observed could be blocked in 32 All of the compounds were equally synthetically accessible and easy to purify and administer. The 12 compounds studied had similar affinities, in the low nanomolar range, similar to the majority of the PSMA-binding imaging agents we have developed to date. 16, 22, 25 The rationale for the use of these different chelators was to exploit the different coordination chemistry of Tc-oxo compounds. Elevated renal radioactivity generally observed with 99m Tc-oxo complexes was further compounded by the high level of PSMA expression in murine kidney. 38 Changing the chelator also allows manipulation of the overall charge, while molecular weight and lipophilicity of these compounds can be altered with minor modifications in the linker. In agreement with previously published results on chelate stability and in vivo performance of different bioconjugates such as affibodies 39 and peptides 40−42 using same the 99m
Tc-labeling core, we observed significant changes in the biodistribution pattern mostly in nonspecific tissue rather than in PSMA-specific tumor uptake.
SPECT imaging revealed that [
99m Tc]L8, the most hydrophilic radioligand in the tricarbonyl series, had high and specific tumor uptake in the PSMA+ PC3 PIP tumor and long tumor retention of radioactivity, with nearly 82% of the initial uptake (30 min) retained even at 5 h postinjection. This is a significant improvement over the previous lead compound [ 99m Tc]L1, where radiotracer was nearly completely cleared from tumor by 5 h postinjection. 16 Compound [ 99m Tc]L8 showed low uptake in normal tissues such as liver and gallbladder at late time points. Rapid clearance observed from blood suggested that there was no transchelation to blood proteins. Similarly rapid clearance was also observed from liver, spleen, and kidney. Because the tumor models were derived from isogenic human PC3 PCa cells and are relatively uniform in size and location, 43 we surmise that the overall neutral charge, small size of the chelating agent, and relative hydrophilicity of L8 contributed to the high and specific binding to PSMA with rapid clearance from normal tissues.
The most striking feature of the 99m Tc-oxo series is the high and prolonged uptake within spleen, which was not observed for radioligands employing the tricarbonyl chelator. We hypothesize that elevated spleen uptake and retention could be related to binding to a homologue of PSMA, namely glutamate carboxypeptidase III (GCPIII), which has recently been described. 44, 45 GCPIII is highly expressed in spleen, testis, and kidney 46 and has been shown to be a target of some low molecular weight antagonists of PSMA. 47 Because none of these antagonists are specific for GCPIII, our blocking studies with 2-PMPA, which has demonstrated affinity to GCPIII, and ZJ43 are not conclusive regarding GCPIII-mediated binding. Blocking studies performed for [
99m Tc]L15 in blood, spleen, and kidney do indicate GCPII-and/or GCPIII-mediated tissue uptake. However, because blocking was >90% for both compounds, a significantly greater element of blocking for 2-PMPA could not be demonstrated, which may have suggested a GCPIII-specific element. In a recent preclinical study, high spleen and kidney uptake by a 68 Ga-labeled Lys-Glu urea-based PSMA PET agent using N,N′-bis[2-hydroxy-5-(carboxyethyl)-benzyl]ethylenediamine-N,N′-diacetic acid (HBED-CC) as the chelating agent has been reported. 48 However, the first clinical study of this agent demonstrated only moderate uptake within spleen, which did not interfere with detection of putatively PSMA+ lesions. 49 These findings suggest that a species-related difference, perhaps due to differential expression of GCPIII, exists and that elevated uptake in some nontarget sites such as spleen in preclinical rodent studies may not apply to clinical studies.
Considerations for clinical translation of one or more of the radioligands studied herein, or other compounds of this class, include: (1) high concentration within tumor (% ID/g), (2) high binding specificity (PSMA+ PC3 PIP to PSMA− PC3 flu uptake ratio), (3) longer retention in PSMA+ PC3 PIP vs kidney, and (4) low liver and gastrointestinal uptake. While difficult to optimize for all of these parameters concurrently, the compounds synthesized in this small series could be ranked with respect to their desirability for translation. Tc-labeled agent, for compounds of this class and likely for those intended for other biomedically important targets.
■ EXPERIMENTAL SECTION
A detailed description of general experimental methods is included in the Supporting Information.The purity of tested compounds as determined by analytical HPLC with absorbance at 220 nm was >95%.
(3S,7S,22S)-26-(4-(2-Amino-2-carboxyethyl)-1H-1,2,3-triazol-1-yl)-5,13,20-trioxo-4,6,12,21-tetraazahexacosane-1,3,7,22-tetracarboxylic Acid, L8. To a solution of Fmoc-Lys(N 3 )-OH (0.25 g, 0.63 mmol in 8 mL of 2/1 t-BuOH/H 2 O), was added Boc-L-propargylglycine·DCHA (0.25 g, 0.63 mmol in 2 mL of 2/1 tBuOH/H 2 O), followed by sodium ascorbate (4.75 mg, 0.024 mmol in 1 mL water) and Cu(OAc) 2 ·H 2 O (2 mg, 0.012 mmol in 1 mL water) and the mixture stirred at room temperature for 12 h under N 2 at 30°C
. Quadrapure-IDA resin (20 mg) was added to the solution and was gently shaked using mechanical shaker at rt for 2 h to remove Cu(II). The solution was filtered through a Celite bed, and the light-yellow filtrate was evaporated to dryness. The solid residue was thus obtained was partitioned between EtOAc and water. The aqueous phases were re-extracted with EtOAc. The organic phases were combined, dried over Na 2 SO 4 , and evaporated. The crude product was used without any purification in the next step where the Fmoc group was removed using 20/80 piperidine/DMF solution at rt to produce 1. Compound 1 was purified using C 18 
Compound L9 was prepared following Scheme 2 in a total of six steps as described below. Compound 3 was synthesized using commercially available FmocLys(Boc)-OH and 4-methoxy-benzylchloride in presence of cesium carbonate in DMF at rt. 16 Selective removal of Boc from 3 was performed using p-toluenesulfonic acid. 16 Briefly, a solution of 3 (2 g, 3.40 mmol in 20 mL EtOAc) was cooled to 0−2°C in an ice bath, and p-toluenesulfonic acid monohydrate (0.64 g, 2.60 mmol) in 5 mL of absolute ethanol was added. The cooling bath was removed, and the reaction mixture was allowed to warm to room temperature for 2 h. The reaction mixture was then concentrated to a thick oil under reduced pressure, and the mixture was purified by flash chromatography using 5/95 MeOH/CH 2 Cl 2 to afford product 4 as colorless solid in 55% (1.24 g, 1.87 mmol) yield. ESIMS m/z: 660 [M] + . A solution of 4 (0.66 g, 1 mmol, in 40 mL CH 2 Cl 2 ) was neutralized with TEA (140 μL, 1.5 mmol) and was cooled at 4°C by ice-bath. A solution of pyridine-2-aldehyde (0.086g, 0.8 mmol) was added slowly to the ice cold solution of 4 for a period of 30 min and was stirred for another 30 min. Then ice-bath was removed and the solution was stirred at rt for 2 h. Sodium triacetoxyborohydride (0.43 g, 2 mmol) was added portionwise to the reaction mixture followed by acetic acid (126 μL, 2 mmol) and left for 16 h. Solvent was removed under vacuum, and the residue was dissolved in dichloromethane and extracted with 3 × 50 mL of water. Organic layer was dried under vacuum and purified via a silica gel column using 4−5% methanol/CH 2 Cl 2 as an eluent to obtain compound 5 in ∼40%, 0.232 g (0.4 mmol) yield. ESI-MS: 580 [M + 1] + . A solution of 5 (0.1 g, 0.17 mmol in 20 mL DMF) was cooled to 4°C . To this was added t-butyl bromoacetate (32 μL,0.17 mmol), potassium iodide (0.028g, 0.17 mmol), and diisopropyl ethylamine (30 μL, 0.17 mmol), respectively, and the mixture stirred for 2 h. The icebath was removed, and the mixture was stirred for 2 days at rt. The solvent was removed under vacuum, and the residue was dissolved in 50 mL of ethyl acetate and washed with 3 × 50 mL water. The organic layer was concentrated under vacuum and purified via a silica gel column using 20/80−30/70 EtOAc/CH 2 Cl 2 as eluent. Thus, 6 was obtained in 33% (0.039 g) yield. Compound 6 was treated with 4 mL 1/1 TFA/CH 2 Cl 2 at rt for 2 h to simultaneously remove Boc and tbutyl groups. After solvent removal, crude solid was lyophilized and treated with 2 mL of 20/80 piperidine/DMF at rt for 20 min. Solvent was removed under vacuum. The colorless crude material was dissolved in water (20 mL) and extracted with ethyl acetate (3 × 10 mL). Compound 7 was obtained from the water layer in 48% yield. Compound 7 was further purified via C 18 solid phase extraction. 1 (0.020 g, 0.0.034 mmol in 100 μL of DMF) was added to a stirred solution of 5 (0.010 g, 0.034 mmol in 100 μL DMF) at rt followed by the addition of DIEA (0.05 μL, 0.034 mmol). The reaction mixture was left for 3 h at room temperature. The reaction mixture was then concentrated under reduced pressure dissolved in 1 mL of water and purified by HPLC using a isocratic method of 80/20 water (0.1% TFA)/acetonitrile (0.1% TFA) as mobile phase, flow rate 4 mL/min; R t , 14 min. 16 Briefly, Fmoc-Lys-OH was reacted with imidazole-2 aldehyde in the presence of NaBH(OAc) 3 and acetic acid in dichoroethane. Solution was stirred for 20 h. The product was diluted with CH 2 Cl 2 and washed with water. The solid residue obtained after evaporation of the organic layer was further purified by SiO 2 column chromatography using 20/80 MeOH/ CH 2 Cl 2 as eluant. Fmoc removal of the compound was performed using a 20/80 piperidine/DMF solution. After solvent removal, compound was purified using a C 18 solid phase extraction using 90/10 H 2 O/CH 3 CN as eluant. ESI-MS 307 [M + H] + . Compound 8 (10 mg, 0.03 mmol in 1 mL DMF) was added to a solution of 2 (28 mg, 0.06 mmol) and DIEA (50 μL) and left for 2 h at rt. After solvent evaporation, product was purified using a C 18 column. The compound was further purified by HPLC using same method as L8, R t , 13.5 min. 1 Synthesis of L11−L18. These compounds were prepared following a combined solid phase and solution phase synthetic strategy as described for L11.
. Lys(Boc)-Wang resin (250 mg, 0.43 mmol) was allowed to swell with CH 2 Cl 2 (3 mL) followed by DMF (3 mL). A solution of 20% piperidine in DMF (3 × 3 mL) was added to the resin, followed by gently shaking on a mechanical shaker for 30 min at ambient temperature. The resin was washed with DMF (3 × 3 mL) and CH 2 Cl 2 (3 × 3 mL). Formation of free amine was assessed by the Kaiser test. 50 After swelling the resin in DMF, a solution of Fmoc-Gly-OH (3 equiv), HBTU (3 equiv), HOBt (3 equiv), and DIPEA (4.0 equiv) in DMF was added and gently shaken for 2 h. The resin was then washed with DMF (3 × 3 mL). The coupling efficiency was assessed by the Kaiser test. The aforementioned sequence was repeated for two more coupling steps with FmocGly-OH. Final compound was cleaved from the resin using TFA/ CH 2 Cl 2 /TES (1:1:0.02) and concentrated under vacuum to produce 9. The concentrated product was purified by using a C 18 26 Briefly, compound L11 (1 mg, 75.3 μmol) was dissolved in 1 mL of 0.5 M ammonium acetate buffer at pH 8. Disodium tartrate dihydrate was dissolved in the labeling buffer of 0.5 M ammonium acetate (pH 8.5) to a concentration of 50 mg/mL. Ascorbic acid−HCl solution was prepared by dissolving ascorbic acid in 10 mM HCl to a concentration of 3.0 mg/mL. A fresh 4 mg/mL SnCl 2 was prepared using ascorbic− HCl solution. A solution of L11 (80 μL) was combined to a solution of 50 μL of 0.25 M ammonium acetate and 20 μL of tartrate buffer. This solution was purged with N 2 for 2 min. To this solution was added the SnCl 2 solution (10 μL) ,and pH of the solution was adjusted ∼8−8.5. Radiolabeling of L19. Tricine was used as coligand for HYNIC labeling. Radiolabeling for ligands L19 was performed following a literature procedure. 51 Briefly, to 50 μL of HYNIC ligand (2 mg/mL) was added 50 μL of 0.5 M NaHCO 3 and 100 μL of tricine (7 mg/mL in water), and the solution was purged with N 2 for 2 min. Na 99m TcO4 (185 mBq/5 mCi in 200 μL saline) and 10 μL of freshly prepared SnCl 2 (1 mg/mL in 10 mM HCl) were added to the solution and left at rt for 30 min. HPLC method 5 was used to isolate [ 99m Tc]L19. Radiolabeled product was obtained in ∼60% yield and ∼95% purity.
Formulation. All radiolabled products were neutralized with ∼20− 30 μL of 1 M sodium bicarbonate and evaporated to dryness under vacuum. The obtained solid residues was dissolved in 200 μL of saline and used for imaging and biodistribution studies after appropriate dilution with saline.
Cell Lines. Sublines of the androgen independent PC3 human PCa cell line, originally derived from an advanced androgen independent bone metastasis, were used. These sublines have been modified to express high (PC3 PIP) or possess low (PC3 flu) levels of PSMA and were generously provided by Dr. Warren Heston (Cleveland Clinic). PSMA-expressing (PC3 PIP), nonexpressing (PC3 flu) PCa cell lines were grown in RPMI 1640 medium (Corning Cellgro, Manassas, VA) containing 10% fetal bovine serum (FBS) (Sigma-Aldrich, St.Louis, MO) and 1% penicillin−streptomycin (Corning Cellgro, Manassas, VA). All cell cultures were maintained in an atmosphere containing 5% carbon dioxide (CO 2 ) at 37.0°C in a humidified incubator.
NAALADase Assay. The PSMA inhibitory activity of L8−L19 and ReL8 were determined using a fluorescence-based assay according to a previously reported procedure. 22 Briefly, lysates of LNCaP cell extracts (25 μL) were incubated with the inhibitor (12.5 μL) in the presence of 4 μM N-acetylaspartylglutamate (NAAG) (12.5 μL) for 120 min. The amount of the glutamate released by NAAG hydrolysis was measured by incubating with a working solution (50 μL) of the Amplex Red Glutamic Acid Kit (Life Technologies, Grand Island, NY) for 60 min. Fluorescence was measured with a VICTOR3 V multilabel plate reader (Perkin-Elmer Inc., Waltham, MA) with excitation at 490 nm and emission at 642 nm. Inhibition curves were determined using semilog plots, and IC 50 values were determined at the concentration at which enzyme activity was inhibited by 50%. Enzyme inhibitory constants (K i values) were generated using the Cheng−Prusoff conversion. 52 Assays were performed in triplicate. Data analysis was performed using GraphPad Prism version 4.00 for Windows (GraphPad Software, San Diego, California).
Tumor Models. Animal studies were carried out in full compliance with the regulations of the Johns Hopkins Animal Care and Use Committee. The 6−8-week-old male, nonobese diabetic (NOD)/ severe-combined immunodeficient (SCID) mice (Johns Hopkins Immune Compromised Core) were implanted subcutaneously (sc) with PC3 PIP (PSMA+) and PC3 flu (PSMA−) cells (2 × 10 6 in 100 μL of HBSS (Corning Cellgro, Manassas, VA) at the forward right and left flanks, respectively. Mice were imaged or used in ex vivo biodistribution assays when the xenografts reached 5−7 mm in diameter.
SPECT-CT Imaging of PSMA+ PC3 PIP and PSMA− PC3 flu Xenografts. Compounds [ 99m Tc]L8−L19 were imaged in PSMA+ PC3 PIP and PSMA− PC3 Flu xenograft models. Mice (N = 2) were injected via the tail vein with approximately 37 MBq (1 mCi) of radiotracer formulated in 100 μL of saline at pH ∼ 7. Mice were anesthetized with 3% isofluorane, placed in the scanner, and maintained at 1% isoflurane throughout the imaging procedure. A Gamma Medica-Ideas (Northridge, CA) X-SPECT scanner equipped with two opposing low-energy 0.5 mm aperture pinholes and tunable CT was used for all scans. Mice were scanned over 180°in 5.5°, 30 s increments. A CT scan was performed prior to or after scintigraphy for anatomical coregistration. Data were reconstructed and fused using commercial software from the vendor (Gamma Medica-Ideas), which includes a 2D-ordered subsets-expectation maximum (OS-EM) algorithm. Volume rendered images were generated using Amira software (http://www.vsg3d.com/amira).
In Vivo Binding Specificity. . At 30 min and 1, 2, and 5 h postinjection, mice were sacrificed after which heart, lungs, liver, stomach, pancreas, spleen, fat, kidney, muscle, small and large intestines, urinary bladder, PSMA+ PC3 PIP and PSMA− PC3 flu tumors, and a 0.1−0.2 mL aliquot of blood were collected. Each organ was weighed, and the tissue radioactivity was measured with an automated gamma counter (1282 Compugamma CS, Pharmacia/LKBNuclear, Inc., Gaithersburg, MD). The percentage of injected dose per gram of tissue (% ID/g) was calculated by comparison with samples of a standard dilution of the initial dose. All measurements were corrected for decay.
Data Analysis. Data are expressed as mean ± standard deviation (SD). Prism software (GraphPAD, San Diego, California) was used to determine statistical significance. Statistical significance was calculated using a paired t test. A P-value <0.0001 was considered significant.
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